N. K. Cheung and M. A. Dyer, Neuroblastoma: developmental biology, cancer genomics and immunotherapy, Nat. Rev. Cancer, vol.13, pp.397-411, 2013.

M. Jiang, J. Stanke, and J. M. Lahti, The connections between neural crest development and neuroblastoma, Curr. Top. Dev. Biol, vol.94, pp.77-127, 2011.

J. Shohet, J. Foster, and . Neuroblastoma, BMJ, vol.357, 1863.

M. Schwab, Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour, Nature, vol.305, pp.245-248, 1983.

I. Janoueix-lerosey, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma, Nature, vol.455, pp.967-970, 2008.

Y. P. Mosse, Identification of ALK as a major familial neuroblastoma predisposition gene, Nature, vol.455, pp.930-935, 2008.

V. Van-limpt, A. Chan, A. Schramm, A. Eggert, and R. Versteeg, Phox2B mutations and the Delta-Notch pathway in neuroblastoma, Cancer Lett, vol.228, pp.59-63, 2005.

M. Holzel, NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome, Cell, vol.142, pp.218-229, 2010.

M. Sausen, Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma, Nat. Genet, vol.45, pp.12-17, 2013.

T. J. Pugh, The genetic landscape of high-risk neuroblastoma, Nat. Genet, vol.45, pp.279-284, 2013.

J. J. Molenaar, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes, Nature, vol.483, pp.589-593, 2012.

M. Peifer, Telomerase activation by genomic rearrangements in high-risk neuroblastoma, Nature, vol.526, pp.700-704, 2015.

L. J. Valentijn, TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors, Nat. Genet, vol.47, pp.1411-1414, 2015.

T. F. Eleveld, Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations, Nat. Genet, vol.47, pp.864-871, 2015.

A. Schramm, Mutational dynamics between primary and relapse neuroblastomas, Nat. Genet, vol.47, pp.872-877, 2015.

S. N. Grobner, The landscape of genomic alterations across childhood cancers, Nature, vol.555, pp.321-327, 2018.

X. Ma, Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours, Nature, vol.555, pp.371-376, 2018.

G. M. Brodeur and R. Bagatell, Mechanisms of neuroblastoma regression, Nat. Rev. Clin. Oncol, vol.11, pp.704-713, 2014.

S. B. Baylin and P. A. Jones, Epigenetic Determinants of Cancer, Cold Spring Harb. Perspect. Biol, vol.8, 2016.

Q. Yang, Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome, Clin. Cancer Res, vol.13, pp.3191-3197, 2007.

Q. Yang, Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma, Clin. Cancer Res, vol.10, pp.8493-8500, 2004.

P. Lazcoz, Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma, BMC Cancer, vol.6, 2006.

J. Hoebeeck, Aberrant methylation of candidate tumor suppressor genes in neuroblastoma, Cancer Lett, vol.273, pp.336-346, 2009.

J. Charlet, Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma, Mol. Carcinog, vol.56, pp.1290-1301, 2017.

C. Wang, EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR, Cancer Res, vol.72, pp.315-324, 2012.

D. Dreidax, Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis, Hum. Mol. Genet, vol.22, pp.1735-1745, 2013.

C. D. Margetts, Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma, Endocr. Relat. Cancer, vol.15, pp.777-786, 2008.

P. G. Buckley, Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions, Int. J. Cancer, vol.128, pp.2296-2305, 2011.

H. Caren, Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma, BMC Cancer, vol.11, 2011.

A. Decock, Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers, Genome Biol, vol.13, 2012.

G. Mayol, DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis, PLoS ONE, vol.7, 2012.

S. Gomez, DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights, Epigenomics, vol.7, pp.1137-1153, 2015.

M. Olsson, S. Beck, P. Kogner, T. Martinsson, and H. Caren, Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors, Epigenetics, vol.11, pp.74-84, 2016.

K. O. Henrich, Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas, Cancer Res, vol.76, pp.5523-5537, 2016.

K. Durinck and F. Speleman, Epigenetic regulation of neuroblastoma development, Cell Tissue Res, vol.372, pp.309-324, 2018.

K. C. Lim, Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system, Nat. Genet, vol.25, pp.209-212, 2000.

T. Moriguchi, Gata3 participates in a complex transcriptional feedback network to regulate sympathoadrenal differentiation, Development, vol.133, pp.3871-3881, 2006.

K. Tsarovina, Essential role of Gata transcription factors in sympathetic neuron development, Development, vol.131, pp.4775-4786, 2004.

M. H. Lentjes, The emerging role of GATA transcription factors in development and disease, Expert Rev Mol Med, vol.18, 2016.

J. J. Molenaar, Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells, Oncogene, vol.29, pp.2739-2745, 2010.

N. Hu, P. H. Strobl-mazzulla, and M. E. Bronner, Epigenetic regulation in neural crest development, Dev. Biol, vol.396, pp.159-168, 2014.

M. Simoes-costa and M. E. Bronner, Insights into neural crest development and evolution from genomic analysis, Genome Res, vol.23, pp.1069-1080, 2013.

P. S. Yan, CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer, Clin. Cancer Res, vol.6, pp.1432-1438, 2000.

J. R. Carr, FoxM1 regulates mammary luminal cell fate, Cell Rep, vol.1, pp.715-729, 2012.

X. L. Liu, TGFBR3 co-downregulated with GATA3 is associated with methylation of the GATA3 gene in bladder urothelial carcinoma, Anat Rec (Hoboken), vol.296, p.1717, 2013.

L. Fransecky, Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL, J. Hematol. Oncol, vol.9, 2016.

N. K. Mukhopadhyay, Plk1 Regulates the Repressor Function of FoxM1b by inhibiting its Interaction with the Retinoblastoma Protein, Scientific reports, vol.7, 2017.

H. Zhang, Profiling of human CD4+ T-cell subsets identifies the TH2-specific noncoding RNA GATA3-AS1, J. Allergy Clin. Immunol, vol.132, pp.1005-1008, 2013.

H. R. Gibbons, Divergent lncRNA GATA3-AS1 Regulates GATA3 Transcription in T-Helper 2 Cells, Front Immunol, vol.9, 2018.

H. Peng, Essential role of GATA3 in regulation of differentiation and cell proliferation in SK-N-SH neuroblastoma cells, Molecular medicine reports, vol.11, pp.881-886, 2015.

D. A. Oldridge, Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism, Nature, vol.528, pp.418-421, 2015.

P. Fagone, F. Nicoletti, G. M. Vecchio, R. Parenti, and G. Magro, Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis, Acta Histochem, vol.117, pp.820-823, 2015.

J. J. Molenaar, Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma, Cancer Res, vol.68, pp.2599-2609, 2008.

L. Shan, GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation, Oncogene, vol.33, pp.3205-3216, 2014.

V. Boeva, Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries, Nat. Genet, vol.49, pp.1408-1413, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01741718

T. Groningen, Neuroblastoma is composed of two super-enhancer-associated differentiation states, Nat. Genet, vol.49, pp.1261-1266, 2017.

D. Nonaka, B. Y. Wang, D. Edmondson, E. Beckett, and C. C. Sun, A study of gata3 and phox2b expression in tumors of the autonomic nervous system, Am. J. Surg. Pathol, vol.37, pp.1236-1241, 2013.

A. B. Wiles, GATA3 is a reliable marker for neuroblastoma in limited samples, including FNA Cell Blocks, core biopsies, and touch imprints, Cancer Cytopathol, vol.125, pp.940-946, 2017.

J. Charlet, M. Szemes, K. T. Malik, and K. W. Brown, MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma, Mol. Carcinog, vol.53, pp.413-420, 2014.

S. Thomas, Human neural crest cells display molecular and phenotypic hallmarks of stem cells, Hum. Mol. Genet, vol.17, pp.3411-3425, 2008.